2018 5 29 5 Chin J Aesth Plast Surg, May 2018 Vol. 29 No. 5 5-1 2013 [6] [1] Mustoe 2002 [2] 2010,O gawa [3] Gold 2014 [4-5] 2010 2016 3 DOI:10.3969/j.issn.1673-7040.2018.05.001 81671921 201502028 Email:liuwei_md@126.com
5-2 2018 5 29 5 Chin J Aesth Plast Surg, May 2018 Vol. 29 No. 5 2 15 1 [7] 16 16 [8] 16 1 1 1
2018 5 29 5 Chin J Aesth Plast Surg, May 2018 Vol. 29 No. 5 5-3 3 / 6 4 11 p53 [9-10] [11] [12] Fas Minor red/raised 4 Major dark/raised 4.1 [5] ( / <2.0 cm )4 [13] minor major 3 ⑴ <2.0 cm ⑵ 2.0~10.0 cm <5.0 cm 5 5- fluorouracil, 5- FU ⑶ >10.0 cm 5.0 cm 5- FU 2 4.2 4 2 5 3
5-4 2018 5 29 5 Chin J Aesth Plast Surg, May 2018 Vol. 29 No. 5 2 2 4.3 ⑴ ⑵ + 12 5 5- FU 2014 2.0~10.0 cm <5.0 cm [4-5] 5- FU [14-17] 5- FU [18-20] Meta 3 [21] 5- FU [22-29] 10 11
2018 5 29 5 Chin J Aesth Plast Surg, May 2018 Vol. 29 No. 5 5-5 6 5- FU [30] 5- FU 5- FU 5- FU 2 3 10 24 h 6 1 5- FU 24 h 2 12 5- FU 10 5- FU 6 3 3
5-6 2018 5 29 5 Chin J Aesth Plast Surg, May 2018 Vol. 29 No. 5 6 >10.0 cm >5.0 cm <5.0 cm [31] 6.1 5- FU 2 3 [32] / 2 5- FU 4 6.2 5- FU 1 24 h 5- FU 12 5- FU 14 4 7 /
2018 5 29 5 Chin J Aesth Plast Surg, May 2018 Vol. 29 No. 5 5-7 4 4 16 5- FU 5- FU + [31] <1.5 cm 8 2.0 cm 12
5-8 2018 5 29 5 Chin J Aesth Plast Surg, May 2018 Vol. 29 No. 5 5 9 / 5 5 [21-29] 5- FU [14-17] 5- FU [33-36] 5- FU 10 50%, 63% 10.1 5- FU ⑴ 5- FU 5- FU [2] 2002 2~5 mg/ml 0.6 ml 5- FU 25 mg/ml 2% 5.0 ml [2] 2014 [4-5] 5- FU 2013 5- FU ⑵5- FU 5- FU 5.0 ml [6] 5- FU 10 mg/ml 5- FU 0.6 ml 2006 5- FU 2% 1.0 ml [18] 2002 5- FU ⑶5- FU 7 mg/ml 1.0 ml 5- FU 0.1 ml 2% 0.5 ml 5- FU 5- FU ⑷
2018 5 29 5 Chin J Aesth Plast Surg, May 2018 Vol. 29 No. 5 5-9 5- FU 5 mg/ml 1 10.2 5- FU 1 5- FU+ 5- FU 5- FU 4 1 6 6 8 12 1 11 2002 2014 + 5- FU 5- FU 5- FU 10.3 5- FU ⑴ 5- FU 5- FU 25 mg/ml 5- FU 0.6 ml +2% 5.0 ml 4 1 ⑵ 3 6 8 12 1 5- FU + 1 10.4 5- FU 12 ⑴ 5- FU [37] [1] [38] ⑵ [39] 5- FU 5- FU 0.6 ml+2% 5.0 1 5- FU 0.6 ml+2% 1.0 5.0 ml 5- FU 5- FU 0.6 ml +2% 5.0 ml 5- FU 0.3 ml +2% 2.0~3.0 ml+ 2.0~3.0 ml 5- FU 0.1 ml+2% 0.5 1.0 ml 5- FU 0.1 ml +2% 1.0~2.0 ml+ 0.5~1.0 ml 5- FU 25 mg/ml 10 mg/ml 7
5-10 2018 5 29 5 Chin J Aesth Plast Surg, May 2018 Vol. 29 No. 5 12.1 2 ⑴ 17.5~20.0 Gray 4 5 1 /d [38 43] ⑵ X 18.0 Gray, 2 1 [44] 2 1 6-7MeV X X 2 1 2 [44] X 2 2 12.2 X ⑴ 12.4 ⑴ 24 h 48 h ⑵ 1.0 cm 24 h 48 h ⑶ ⑵ 1 d [40] 7 d 2 ⑷ ⑶ ⑸ 24 h 48 h ⑹ ⑷ 12.3 [38-44] ⑸ biological effective dose, BED BED>30 Gray [42] 10% EBD X ⑹ 16 ⑺ 13
2018 5 29 5 Chin J Aesth Plast Surg, May 2018 Vol. 29 No. 5 5-11 5- FU ( ) [45] 5- FU 5- FU+ 14 2002 2014 1 Al- Attar A, Mess S, Thomassen JM, et al. Keloid pathogenesis and treatment[ J ]. Plast Reconstr Surg, 2006,117(1):286-300. 2 Mustoe TA, Cooter RD, Gold MH, et al. International clinical recommendations on scar management [ J ]. Plast Reconstr Surg, 2002,110(2):560-571. 3 Ogawa R. The most current algorithms for the treatment and prevention of hypertrophic scars and keloids [ J ]. Plast Reconstr Surg, 2010,125(2):557-568. 4 Gold MH, Berman B, Clementoni MT, et al. Updated international [46-47] clinical recommendations on scar management: part 1- - evaluating the evidence[ J ]. Dermatol Surg, 2014,40(8):817-824. [48-49] 5 Gold MH, McGuire M, Mustoe TA, et al. Updated international 15 clinical recommendations on scar management: part 2- - algorithms for scar prevention and treatment [ J ]. Dermatol Surg, 2014,40(8): 825-831. 6 Kim S, Choi TH, Liu W, et al. Update on scar management: guidelines for treating Asian patients [ J ]. Plast Reconstr Surg, 2013,132(6):1580-1589. 7,. [ J ]., 2008,17(2):289-302. 8 Kimura K, Inadomi T, Yamauchi W, et al. Dermatofibrosarcoma protuberans on the chest with a variety of clinical features masquerading as a keloid: is the disease really protuberant? [ J ]. Ann Dermatol, 2014,26(5):643-645. 9,,,. p53 [4-5] [, J ]. 2004,20(2):85-87. 10 Saed GM, Ladin D, Olson J, et al. Analysis of p53 gene mutations in keloids using polymerase chain reaction- based single- strand conformational polymorphism and DNA sequencing [ J ]. Arch Dermatol, 1998,134(8):963-967. 11,,. Fas [, J ]. 2007,21(7):698-7 12 Kim A, DiCarlo J, Cohen C, et al. Are keloids really gli- loids?:
5-12 2018 5 29 5 Chin J Aesth Plast Surg, May 2018 Vol. 29 No. 5 High- level expression of gli- 1 oncogene in keloids[ J ]. J Am Acad Dermatol, 2001,45(5):707-711. 13. [ J ]., 32 Li W, Wang Y, Wang X, et al. A keloid edge precut, 2016,25(6):38-40. 14 Khan MA, Bashir MM, Khan FA. Intralesional triamcinolone alone and in combination with 5- fluorouracil for the treatment of keloid andhypertrophicscars[j]. JPakMedAssoc, 2014,64(9):1003-1007. 15 Darougheh A, Asilian A, Shariati F. Intralesional triamcinolone alone or in combination with 5- fluorouracil for the treatment of keloidand hypertrophic scars [ J ]. Clin Exp Dermatol, 2009,34(2): 219-223. 16 Sadeghinia A, Sadeghinia S. Comparison of the efficacy of intralesional triamcinolone acetonide and 5- fluorouracil tattooing forthetreatmentofkeloids[j]. DermatolSurg, 2012,38(1):104-109. 17 Davison SP, Dayan JH, Clemens MW, et al. Efficacy of intralesional 5- fluorouracil and triamcinolone in the treatment of keloids [ J ]. Aesthet Surg J, 2009,29(1):40-46. preradiotherapy method in large keloid skin graft treatment [ J ]. Dermatol Surg, 2014,40(1):52-57. 33,,,. 5- [ J ]., 2009,89(16):1102-1105. 34,,,. 5- [ J ]., 2008,4(1):36-38. 35,,,. [ J, ]. 2014,18(46):7427-7431. 36,. 5- [, J ]. 2013,45(3):174-176. 37 Song N, Wu X, Gao Z, et al. Enhanced expression of membrane transporter and drug resistance in keloid fibroblasts [ J ]. Hum 18,,. 5- Pathol, 2012,43(11):2024-2032. [ J ]., 38,. [ J ]. 2006,22(1):44-46., 2016,32(2):158-160. 19,,,. 5- FU 39,,,. [ J ]., 48 [ J, ]. 2004,42(5):288-290. 2007,18(6):437-440. 40 Li W, Wang Y, Wang X, et al. A keloid edge precut, 20 Liu W, Wu X, Gao Z, et al. Remodelling of keloid tissue into normal- looking skin [ J ]. J Plast Reconstr Aesthet Surg, 2008,61 (12):1553-1554. preradiotherapy method in large keloid skin graft treatment[ J ]. Dermatol Surg, 2014,40(1):52-57. 41 Ogawa R, Yoshitatsu S, Yoshida K, et al. Is radiation therapy for 21,. 5- keloids acceptable? The risk of radiation- induced carcinogenesis[ Meta [ J ]., 2013,22 (12): 1294-1299. J ]. Plast Reconstr Surg, 2009,124(4):1196-1201. 42 Kal HB, Veen RE. Biologically effective doses of postoperative 22,. 5- [ J ]. radiotherapy in the prevention of keloids. Dose- effect, 2012,33(4):395-397. relationship[ J ]. Strahlenther Onkol, 2005,181(11):717-723. 23,. 5-43,,,. 107 [, J ]. 2012,12(7):939-940. [ J ]. ( ), 2014,46 (1): 24. 5-56 [ J ]. 169-172., 2011,44(10):747. 44 Shen J, Lian X, Sun Y, et al. Hypofractionated electron- beam 25,. radiation therapy for keloids: retrospective study of 568 cases with [, J ]. 2006,34(4):390-. 391 834 lesions[ J ]. J Radiat Res, 2015,56(5):811-817. 26. 45,,,. 5- Fu [, J ].. 2004,1(3):208-209 [ J ]., 27,. 2014,35(4):473-475. [ J, ]. 2012,40(3):634. - 636 28,,,., 2003,17 (5):323-324. 29,. [ J ]., 2006,15 (10): 1126-1128. 30 Uppal RS, Khan U, Kakar S, et al. The effects of a single dose of 5- fluorouracil on keloid scars: a clinical trial of timed wound irrigation after extralesional excision [ J ]. Plast Reconstr Surg, 2001,108(5):1218-1224. 31 Wang Y, Xu J, Wu H, et al. Recurrence of large subcutaneous keloids after tissue expansion: two case reports[ J ]. J Plast Reconstr Aesthet Surg, 2013,66(2):e58- e59. 46. 5- [ ( J ]. ), 2011(10):69. [ J ]. 47. [, J ]. 2009,11(7):48. - A 5-48,,. [, J ]. 2003,36(6):342-344. 49,,. [, J ]. 2006,20(9):5 2018-04- 05. [ J ]. 5-1- 12.DOI 10.3969/j.issn.1673-7040.2018.05.001.